Bavarian Nordic A/S (BVNRY)

Market Cap	2.31B
Revenue (ttm)	1.02B
Net Income (ttm)	223.97M
Shares Out	n/a
EPS (ttm)	2.83
PE Ratio	10.30
Forward PE	11.75
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Average Volume	5,492
Open	9.71
Previous Close	9.88
Day's Range	9.71 - 9.79
52-Week Range	6.60 - 13.00
Beta	1.10
RSI	21.83
Earnings Date	Nov 14, 2025

About Bavarian Nordic

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV for the treatment of encephalitis viruses. It operates in the Unite...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1992
• Employees: 1,605
• Stock Exchange: OTCMKTS
• Ticker Symbol: BVNRY

Financial Performance

In 2024, Bavarian Nordic's revenue was 5.72 billion, a decrease of -19.06% compared to the previous year's 7.06 billion. Earnings were 987.98 million, a decrease of -33.03%.

Financial numbers in DKK